Glasdegib
Glasdegib (Daurismo, Pfizer Europe MA EEIG) has 1 EU-approved indication in 1 tumour type.
| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| Acute myeloid leukaemia1 | |||
None | + low-dose cytarabine | 1L | Not candidates for standard induction chemotherapy |
Full text of section 4.1 (therapeutic indications)
Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
Label history
6 changes to the Daurismo label since 2022, none of them to the indications. Newest first, in the words of EMA's record of each procedure.
Changes